Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors

J. K. Hicks, J. R. Bishop, K. Sangkuhl, D. J. Muller, Y. Ji, S. G. Leckband, J. S. Leeder, R. L. Graham, D. L. Chiulli, A. LLerena, Todd Skaar, S. A. Scott, J. C. Stingl, T. E. Klein, K. E. Caudle, A. Gaedigk

Research output: Contribution to journalArticle

219 Citations (Scopus)

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).

Original languageEnglish (US)
Pages (from-to)127-134
Number of pages8
JournalClinical Pharmacology and Therapeutics
Volume98
Issue number2
DOIs
StatePublished - Aug 1 2015

Fingerprint

Cytochrome P-450 CYP2D6
Citalopram
Pharmacogenetics
Serotonin Uptake Inhibitors
Genotype
Guidelines
Fluvoxamine
Sertraline
Paroxetine
Major Depressive Disorder
Anxiety Disorders
Safety
Pharmaceutical Preparations
Cytochrome P-450 CYP2C19

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. / Hicks, J. K.; Bishop, J. R.; Sangkuhl, K.; Muller, D. J.; Ji, Y.; Leckband, S. G.; Leeder, J. S.; Graham, R. L.; Chiulli, D. L.; LLerena, A.; Skaar, Todd; Scott, S. A.; Stingl, J. C.; Klein, T. E.; Caudle, K. E.; Gaedigk, A.

In: Clinical Pharmacology and Therapeutics, Vol. 98, No. 2, 01.08.2015, p. 127-134.

Research output: Contribution to journalArticle

Hicks, JK, Bishop, JR, Sangkuhl, K, Muller, DJ, Ji, Y, Leckband, SG, Leeder, JS, Graham, RL, Chiulli, DL, LLerena, A, Skaar, T, Scott, SA, Stingl, JC, Klein, TE, Caudle, KE & Gaedigk, A 2015, 'Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors', Clinical Pharmacology and Therapeutics, vol. 98, no. 2, pp. 127-134. https://doi.org/10.1002/cpt.147
Hicks, J. K. ; Bishop, J. R. ; Sangkuhl, K. ; Muller, D. J. ; Ji, Y. ; Leckband, S. G. ; Leeder, J. S. ; Graham, R. L. ; Chiulli, D. L. ; LLerena, A. ; Skaar, Todd ; Scott, S. A. ; Stingl, J. C. ; Klein, T. E. ; Caudle, K. E. ; Gaedigk, A. / Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. In: Clinical Pharmacology and Therapeutics. 2015 ; Vol. 98, No. 2. pp. 127-134.
@article{209a0e1971784348a152843d5a9ddcba,
title = "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors",
abstract = "Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).",
author = "Hicks, {J. K.} and Bishop, {J. R.} and K. Sangkuhl and Muller, {D. J.} and Y. Ji and Leckband, {S. G.} and Leeder, {J. S.} and Graham, {R. L.} and Chiulli, {D. L.} and A. LLerena and Todd Skaar and Scott, {S. A.} and Stingl, {J. C.} and Klein, {T. E.} and Caudle, {K. E.} and A. Gaedigk",
year = "2015",
month = "8",
day = "1",
doi = "10.1002/cpt.147",
language = "English (US)",
volume = "98",
pages = "127--134",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors

AU - Hicks, J. K.

AU - Bishop, J. R.

AU - Sangkuhl, K.

AU - Muller, D. J.

AU - Ji, Y.

AU - Leckband, S. G.

AU - Leeder, J. S.

AU - Graham, R. L.

AU - Chiulli, D. L.

AU - LLerena, A.

AU - Skaar, Todd

AU - Scott, S. A.

AU - Stingl, J. C.

AU - Klein, T. E.

AU - Caudle, K. E.

AU - Gaedigk, A.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).

AB - Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).

UR - http://www.scopus.com/inward/record.url?scp=84962294272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962294272&partnerID=8YFLogxK

U2 - 10.1002/cpt.147

DO - 10.1002/cpt.147

M3 - Article

VL - 98

SP - 127

EP - 134

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -